Hutchmed to partner with Epizyme on tumour-targetting treatment Read More
Hutchmed research costs deepen loss; expects US launches in 2022, 2023 Read More
IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial Read More
AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25% Read More
UK earnings, trading statements calendar - next 7 days Read More
AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks Read More
IN BRIEF: Hutchmed tumor drug qualifies for formal review by EU agency Read More
TRADING UPDATES: Smiths gets Euros sticker boost; Hotel Chocolat grows Read More
TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays Read More
TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free Read More
TRADING UPDATES: Topps Tiles improves as curbs ease; Bermele makes buy Read More
IN BRIEF: Hutchmed launches global offering for 104 million shares Read More
IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China Read More
IN BRIEF: Hutchmed launches Hong Kong IPO; drug candidate approved Read More
TRADING UPDATES: Cordiant deploys IPO funds; Scotgold gets loan Read More
TRADING UPDATES: STV looks to summer's football; In The Style sales up Read More
UK shareholder meetings calendar - next 7 days Read More
IN BRIEF: Hutchison China gets USD100 million investment from Baring Read More
IN BRIEF: Hutchison China starts first phase trials for HMPL-306 Read More
TRADING UPDATES: Arden Partners to return to annual profitability Read More
